Dermatology Research
Pediatric Psoriasis Study
Study of Risankizumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis

AGE: 6-18 years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Investigational Treatment Study
CONDITION: Plaque psoriasis
CONDITION: Plaque psoriasis
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Medical Centers
LOCATION: University Hospitals Medical Centers
Learn More About This Research Study
For more information, please contact study coordinator, Dr. Jordon Kahle at 216-844-7305 or complete the form below.
Study Purpose
The purpose of this study is to evaluate Risankizumab compared to Ustekinumab for the treatment of moderate to severe plaque psoriasis who are pediatric candidates for systemic therapy.
Who Can Participate
Participants between 6 and 18 years old with diagnosed with plaque psoriasis and do not have prior exposure to biologic medicines may be eligible for this study.
STUDY ID#
- STUDY20210431